P37231 (PPARG_HUMAN) Homo sapiens (Human)
Peroxisome proliferator-activated receptor gamma UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
301 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Aci… |
Heteromer P19793; Q15596; | 4×ZN; 1×9CR; 1×GW9; | ||||
| Assess | ||||||
| Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retin… |
Heteromer P19793; Q15596; | 1×9CR; 4×ZN; 1×BRL; | ||||
| Assess | ||||||
| Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Aci… |
Heteromer P19793; Q15596; | 4×ZN; 1×9CR; 1×PLB; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding domain complexed with SB1495 |
Heteromer Q15788; | 1×A9C; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with R35 |
Heteromer Q15788; | 1×Q35; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agon… |
Heteromer O75376; | 1×Y5F; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with N-CoR peptide and inverse agon… |
Heteromer O75376; | 1×EEY; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and GW9662 |
Heteromer O75376; | 1×GW9; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and ZINC5672437 |
Heteromer O75376; | 1×XZK; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agon… |
Heteromer O75376; | 1×Y5X; 4×EDO; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with BAY-4931, an inverse agonist (compound 6c) |
Heteromer Q9Y618; | 1×O0U; 2×GOL; 1×CA; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agon… |
Heteromer O75376; | 1×Y5T; 2×EDO; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with SMRT peptide and inverse agoni… |
Heteromer Q9Y618; | 2×EEY; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agon… |
Heteromer O75376; | 2×GOL; 1×Y62; 1×SO4; 8×EDO; 1×K; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agon… |
Heteromer O75376; | 1×Y5O; 3×EDO; | ||||
| Assess | ||||||
| X-ray structure of human PPAR gamma ligand binding domain-lanifibranor-SRC1 coactivator peptide co-… |
Heteromer Q15788; | 1×BJB; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 6a) |
Heteromer Q9Y618; | 1×O2O; | ||||
| Assess | ||||||
| X-ray structure of human PPAR gamma ligand binding domain-bezafibrate co-rystals obtained by co-cry… |
Heteromer Q15788; | 1×PEM; | ||||
| Assess | ||||||
| X-ray structure of human PPAR gamma ligand binding domain-seladelpar-SRC1 coactivator peptide co-cr… |
Heteromer Q15788; | 1×KKB; | ||||
| Assess | ||||||
| X-ray structure of human PPAR gamma ligand binding domain-pemafibrate co-crystals obtained by co-cr… |
Heteromer Q15788; | 1×P7F; | ||||
| Assess | ||||||
| X-ray structure of human PPAR gamma ligand binding domain-fenofibric acid co-crystals obtained by c… |
Heteromer Q15788; | 3×F5A; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding domain complexed with Rosiglitazone |
Heteromer Q15788; | 1×BRL; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding domain complexed with Lobeglitazone |
Heteromer Q15788; | 1×8LX; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding domain complexed with SB1494 |
Heteromer Q15788; | 1×A9F; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactiva… |
Heteromer Q15788; | |||||
| Assess | ||||||
| PPARgamma in complex with a 2-BABA compound |
Heteromer Q61026; | 1×PLB; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative comp… |
Heteromer Q9UBK2; | 1×CTU; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain in complex with SR1664 |
Heteromer Q15788; | 1×3JX; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactiva… |
Heteromer Q15788; | 1×MLI; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of … |
Heteromer Q15788; | |||||
| Assess | ||||||
| PPARg bound to JTP-426467 and Co-R peptide |
Heteromer O75376; | 1×SKL; 2×CXS; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Cerco-A |
Heteromer Q9UBK2; | 1×KRC; | ||||
| Assess | ||||||
| Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by S… |
Heteromer P97947; | 1×BRL; | ||||
| Assess | ||||||
| PPARg bound to T0070907 and Co-R peptide |
Heteromer O75376; | 1×EEY; 2×CXS; 1×SO4; | ||||
| Assess | ||||||
| PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid |
Heteromer P19793; Q15788; | 1×9CR; 1×BRL; | ||||
| Assess | ||||||
| Crystal Structure of PPAR Gamma with N-sulfonyl-2-indole carboxamide ligands |
Heteromer Q15788; | 2×NSI; | ||||
| Assess | ||||||
| THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMM… |
Heteromer P19793; Q15788; | 1×9CR; 1×570; | ||||
| Assess | ||||||
| THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMM… |
Heteromer P19793; Q15788; | 1×9CR; 1×BRL; | ||||
| Assess | ||||||
| Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Rec… |
Heteromer P19793; Q15788; | 1×9RA; 1×D30; | ||||
| Assess | ||||||
| The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalph… |
Heteromer P19793; Q15788; | 1×9CR; 1×544; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form |
Heteromer Q15788; | 1×T53; | ||||
| Assess | ||||||
| Crystal Structure of PPARg in complex with INT131 |
Heteromer Q15788; | 1×Z12; 1×CL; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactiva… |
Heteromer Q15788; | 1×MLA; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form |
Heteromer Q15788; | 1×B05; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form |
Heteromer Q15788; | 1×T51; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib |
Heteromer Q15788; | 1×STI; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form |
Heteromer Q15788; | 1×B4H; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form |
Heteromer Q15788; | 1×6BH; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer Q9UBK2; | 1×21L; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer Q9UBK2; | 1×17L; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with compound 3g |
Heteromer Q9UBK2; | 1×B1O; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with SR10221, an inverse agonist |
Heteromer Q9Y618; | 1×A8R; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with compound 13ab |
Heteromer Q9UBK2; | 1×RTE; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with compound DS-6930 |
Heteromer Q9UBK2; | 1×RTF; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with compound 1l |
Heteromer Q9UBK2; | 1×B0X; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7a) |
Heteromer Q9Y618; | 1×Q2X; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma in complex with Mediator of RNA polymerase II transcription subunit… |
Heteromer Q15648; | 1×EDK; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer Q15788; | 1×CEK; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer Q15788; | 1×FCM; | ||||
| Assess | ||||||
| Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid |
Heteromer Q15788; | 1×ET1; | ||||
| Assess | ||||||
| PPAR mutant complex |
Heteromer Q9UBK2; | 1×EDK; | ||||
| Assess | ||||||
| A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG)… |
Heteromer Q15788; | 1×RO0; 1×GOL; | ||||
| Assess | ||||||
| Design and biological evaluation of novel, balanced dual PPARa/g agonists |
Heteromer Q15788; | 1×CTM; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer Q15788; | 1×24L; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding dmain complexed with S35 |
Heteromer Q15788; | 1×T35; 1×MYR; 1×GOL; | ||||
| Assess | ||||||
| Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists |
Heteromer Q15788; | 1×208; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma complexed with Telmisartan |
Heteromer Q15788; | 1×TLS; | ||||
| Assess | ||||||
| LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA |
Heteromer Q15788; | 1×BRL; | ||||
| Assess | ||||||
| PPAR gamma complex. |
Heteromer Q9UBK2; | 1×EDK; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with TRAP220 peptide and agonist ro… |
Heteromer Q15648; | 1×BRL; | ||||
| Assess | ||||||
| Structural and Biochemical Basis for the Binding Selectivity of PPARg to PGC-1a |
Heteromer Q9UBK2; | 4×SO4; 1×BRL; | ||||
| Assess | ||||||
| Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes |
Heteromer Q15788; | 1×RO7; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactiva… |
Heteromer Q15788; | 1×MLI; | ||||
| Assess | ||||||
| The agonist-free structure of human PPARgamma ligand binding domain in the presence of the SRC-1 co… |
Heteromer Q15788; | 1×MYR; 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPA… |
Heteromer P19793; Q15788; Q92793; | 1×L79; 1×570; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma with compound BR102375K |
Heteromer Q15788; | 2×GOL; 1×A0L; | ||||
| Assess | ||||||
| Revealing a steroid receptor ligand as a unique PPARgamma agonist |
Heteromer Q15788; | 1×486; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929 |
Heteromer Q92793; | 2×EDK; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide |
Heteromer Q15788; | |||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactiva… |
Heteromer Q15788; | 1×MLA; | ||||
| Assess | ||||||
| High-resolution structure of unliganded PPAR gamma in complex with the peptide PGC-1 alpha |
Heteromer Q9UBK2; | |||||
| Assess | ||||||
| Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel sele… |
Heteromer Q9UBK2; | 2×V77; | ||||
| Assess | ||||||
| Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel sele… |
Heteromer Q9UBK2; | 1×7MV; | ||||
| Assess | ||||||
| Molecular recognition of nitro-fatty acids by PPAR gamma |
Heteromer Q15788; | 1×LNA; 1×LNB; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma with compound BR101549 |
Heteromer Q15788; | 1×AE0; | ||||
| Assess | ||||||
| Peroxisome proliferator-activated receptor gamma in complex with VSP-51-2 |
Heteromer Q9UBK2; | 1×SJ9; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactiva… |
Heteromer Q15788; | |||||
| Assess | ||||||
| Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity |
Heteromer Q15788; | 1×0W3; | ||||
| Assess | ||||||
| Ligand binding domain of PPARgamma complexed with Decanoic Acid and PGC-1a peptide |
Heteromer Q9UBK2; | 1×DKA; | ||||
| Assess | ||||||
| Identification of a novel PPARg ligand that regulates metabolism |
Heteromer Q15788; | 1×CTI; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7e) |
Heteromer Q9Y618; | 1×Q33; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7d) |
Heteromer Q9Y618; | 1×Q1R; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative comp… |
Heteromer Q9UBK2; | 1×KK4; | ||||
| Assess | ||||||
| Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound 7e) |
Heteromer Q9Y618; | 1×Q33; | ||||
| Assess | ||||||
| Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound SI-1) |
Heteromer Q9Y618; | 1×Q4O; | ||||
| Assess | ||||||
| Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist |
Heteromer Q15788; | 1×M0T; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with BAY-5516, an inverse agonist |
Heteromer Q9Y618; | 1×Q5O; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with BAY-9683, an inverse agonist |
Heteromer Q9Y618; | 1×Q4C; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 |
Heteromer Q15788; | 1×3T0; | ||||
| Assess | ||||||
| Structure of PPARg H494Y mutant in complex with GW1929 |
Heteromer Q9UBK2; | 1×EDK; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma in complex with compound 13 |
Heteromer Q15788; | 1×14R; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 15b) |
Heteromer Q9Y618; | 1×Q8F; | ||||
| Assess | ||||||
| PPAR gamma LBD bound to SR10221 and SMRT corepressor motif |
Heteromer Q9Y618; | 1×A8R; | ||||
| Assess | ||||||
| Crystal structure of PPARG and NCOR2 with an inverse agonist (compound SI-2) |
Heteromer Q9Y618; | 1×Q5X; 1×SO4; | ||||
| Assess | ||||||
| Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Rece… | homo-4-mer | 2×DRY; | ||||
| Assess | ||||||
| Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Rece… | homo-4-mer | 2×DRD; | ||||
| Assess | ||||||
| 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL | homo-4-mer | 4×072; | ||||
| Assess | ||||||
| PPAR mutant | homo-2-mer | 2×EDK; 4×SO4; | ||||
| Assess | ||||||
| Structure of PPARgamma ligand binding domain in complex with (R)-5-(3-((3-(6-methoxybenzo[d]isoxazo… | homo-2-mer | 2×082; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 (inactive form) | homo-2-mer | 2×WY1; | ||||
| Assess | ||||||
| Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with… | homo-2-mer | 1×DRF; | ||||
| Assess | ||||||
| PPAR mutant | homo-2-mer | |||||
| Assess | ||||||
| Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 | homo-2-mer | 2×PTG; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233 | homo-2-mer | 1×NRO; 2×IMN; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatet… | homo-2-mer | 1×MYI; 2×OCR; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma V290M mutant ligand binding domain in complex with farglitazar | homo-2-mer | 1×570; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with MCC555 | homo-2-mer | 1×MC5; | ||||
| Assess | ||||||
| X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ39 | homo-2-mer | 2×LRA; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding dmain complexed with GW9662 in a covalent bonded form | homo-2-mer | 2×GW9; | ||||
| Assess | ||||||
| X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ46 | homo-2-mer | 1×T0C; | ||||
| Assess | ||||||
| Human PPAR GAMMA ligand binding domain in complex with JKPL35 | homo-2-mer | 1×J35; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain in complex with indomethacin | homo-2-mer | 3×IMN; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutath… | homo-2-mer | 1×GSH; 1×PTG; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain in complex with serotonin | homo-2-mer | 3×SRO; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S | homo-2-mer | 1×M7S; | ||||
| Assess | ||||||
| Crystal structure of PPARgammma in complex with SR1663 | homo-2-mer | 2×3K2; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt28 | homo-2-mer | 1×EK8; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with a synthetic agonist TIPP703 | homo-2-mer | 2×S44; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODI… | homo-2-mer | 2×C08; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-2… | homo-2-mer | 2×NRO; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-… | homo-2-mer | 2×OCR; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-e… | homo-2-mer | 2×OCX; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with JKPL53 | homo-2-mer | 1×J53; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deox… | homo-2-mer | 2×PTG; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate | homo-2-mer | 2×HID; | ||||
| Assess | ||||||
| Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate | homo-2-mer | 5×MYI; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD Q286E mutant | homo-2-mer | 3×GOL; | ||||
| Assess | ||||||
| Human PPARgamma ligand binding domain complexed with Butyrolactone 1 | homo-2-mer | 2×E7C; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator | homo-2-mer | 2×C03; 1×TRS; | ||||
| Assess | ||||||
| LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH… | homo-2-mer | 1×YPA; | ||||
| Assess | ||||||
| The ligand-free structure of human PPARgamma LBD R280C mutant | homo-2-mer | |||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt21 | homo-2-mer | 1×EK1; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with a gammma selective synthetic partial agonist… | homo-2-mer | 2×JJA; | ||||
| Assess | ||||||
| PPARg in complex with inhibitor | homo-2-mer | 2×9WQ; 2×SO4; | ||||
| Assess | ||||||
| Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337) | homo-2-mer | 1×BJB; | ||||
| Assess | ||||||
| Human PPAR Gamma Ligand Binding Domain in complex with a Gammma Selective Synthetic Partial Agonist… | homo-2-mer | 1×JJB; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma in complex with SR1664 | homo-2-mer | 2×3JX; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R | homo-2-mer | 1×M7R; | ||||
| Assess | ||||||
| PPARg in complex with compound 4b | homo-2-mer | 2×HV4; | ||||
| Assess | ||||||
| X-ray Crystal Structure of the PPARgamma Ligand Binding Domain in Complex with Rivoglitazone | homo-2-mer | 1×7VA; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma LBD and the ligand AM-879 | homo-2-mer | 1×BKY; | ||||
| Assess | ||||||
| Structure of PPARgamma ligand binding domain-pioglitazone complex | homo-2-mer | 1×8N6; | ||||
| Assess | ||||||
| Crystal structure of human PPAR-gamma ligand binding domain complex with a potency improved agonist | homo-2-mer | 2×5BC; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma bound to partial agonist nTZDpa | homo-2-mer | 2×NZA; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145 | homo-2-mer | 2×SF1; | ||||
| Assess | ||||||
| X-ray crystal structure of PPARgamma in complex with SR1643 | homo-2-mer | 2×7KK; | ||||
| Assess | ||||||
| Crystal structure of the ligand binding domain of human PPAR-gamma im complex with an agonist | homo-2-mer | 2×3EA; | ||||
| Assess | ||||||
| Crystal structure of the complex of F360L PPARgamma mutant with the ligand LT175 | homo-2-mer | 2×LRG; | ||||
| Assess | ||||||
| Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray cr… | homo-2-mer | 2×SP3; | ||||
| Assess | ||||||
| Crystal structure of V290M PPARgamma mutant in complex with diclofenac | homo-2-mer | 2×DIF; 4×CA; | ||||
| Assess | ||||||
| Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with a Potent and Selective A… | homo-2-mer | 1×2PQ; | ||||
| Assess | ||||||
| Structure of the complex between the F360L PPARgamma mutant and the ligand LT175 (space group I222) | homo-2-mer | 2×LRG; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma complexed with partial agonist SF147 | homo-2-mer | 2×SF2; | ||||
| Assess | ||||||
| Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with an Alpha-Aryloxyphenylac… | homo-2-mer | 1×C01; | ||||
| Assess | ||||||
| Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray cr… | homo-2-mer | 1×SP0; | ||||
| Assess | ||||||
| Crystal Structure of PPARg in complex with T2384 | homo-2-mer | 3×Z27; | ||||
| Assess | ||||||
| Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone | homo-2-mer | 2×BRL; | ||||
| Assess | ||||||
| PPARg bound to inverse agonist H3B-343 | homo-2-mer | 2×TJC; | ||||
| Assess | ||||||
| Structure of PPARgamma ligand binding domain - lobeglitazone complex | homo-2-mer | 2×8LX; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with triphenyltin | homo-2-mer | 2×T9T; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma and the agonist LT160 (ureidofibrate derivative) | homo-2-mer | 1×DRJ; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate der… | homo-2-mer | 1×DRH; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid | homo-2-mer | 1×ZZH; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10638 | homo-2-mer | 1×GDY; | ||||
| Assess | ||||||
| LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SR2067 bound to PPARgamma | homo-2-mer | 1×3E7; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate der… | homo-2-mer | 1×DRH; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 | homo-2-mer | 2×EEY; 2×KNA; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) | homo-2-mer | 1×XCX; | ||||
| Assess | ||||||
| PPARgamma Ligand binding domain complexed with a farglitazar analogue gw4709 | homo-2-mer | 1×GW4; 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma bound to partial agonist MRL24 | homo-2-mer | 2×241; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma ligand binding domain | homo-2-mer | |||||
| Assess | ||||||
| PPARg LBD in Complex with SR1988 | homo-2-mer | 1×FT7; | ||||
| Assess | ||||||
| Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer) | homo-2-mer | 1×LRG; | ||||
| Assess | ||||||
| Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid | homo-2-mer | 1×DKD; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma and the full agonist LT175 | homo-2-mer | 1×LRG; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) | homo-2-mer | 1×GRR; | ||||
| Assess | ||||||
| Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid | homo-2-mer | 1×YRG; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with tributyltin | homo-2-mer | 2×TBY; | ||||
| Assess | ||||||
| Covalent bond formation between ynone moiety of synthetic fatty acid and hPPARg-LBD | homo-2-mer | 3×EJL; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma LBD bound to full agonist MRL20 | homo-2-mer | 2×240; | ||||
| Assess | ||||||
| The Crystal Structure of PPARg from Biortus. | homo-2-mer | 1×EDO; 2×PEG; | ||||
| Assess | ||||||
| Covalent bond formation of synthetic ligand with hPPARg-LBD | homo-2-mer | 1×T65; | ||||
| Assess | ||||||
| Human PPAR Gamma LBD in Complex with Tetrazole Compound N-{3-[(4-methylbenzyl)oxy]benzyl}-2H-tetraz… | homo-2-mer | 2×Y9A; | ||||
| Assess | ||||||
| X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/a… | homo-2-mer | 1×L92; | ||||
| Assess | ||||||
| Covalent bond formation of bifunctional ligand with hPPARg-LBD | homo-2-mer | 1×8XO; | ||||
| Assess | ||||||
| Covalent bond formation between cysteine of PPARg-LBD and iodoacetic acid | homo-2-mer | 2×GOA; | ||||
| Assess | ||||||
| 2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides | homo-2-mer | 1×PLB; | ||||
| Assess | ||||||
| Huisgen cycloaddition for PPARg-LBD labeling by soaking method | homo-2-mer | 1×8Y0; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Troglitazone | homo-2-mer | 1×GD4; | ||||
| Assess | ||||||
| Covalent labeling of hPPARg-LBD by turn-on fluorescent probe mediated by conjugate addition and cyc… | homo-2-mer | 1×EB6; 1×EBF; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma LBD and the ligand NV1362 (7a) | homo-2-mer | 1×QMH; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma LBD and the ligand NV1346 (3a) | homo-2-mer | 1×MX8; | ||||
| Assess | ||||||
| Crystal structure of the complex PPARgamma/AL26-29 | homo-2-mer | 2×65W; | ||||
| Assess | ||||||
| X-ray structure of PPARgamma LBD with the ligand NV1380 | homo-2-mer | 1×H8R; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma LBD and the ligand LJ570: structure obtained fro… | homo-2-mer | 1×AXY; | ||||
| Assess | ||||||
| X-ray crystal structure of PPARgamma in the complex with caulophyllogenin | homo-2-mer | 1×5VN; | ||||
| Assess | ||||||
| Crystal structure of hPPARgamma ligand binding domain complexed with rosiglitazone-based fluorescen… | homo-2-mer | 1×J3F; | ||||
| Assess | ||||||
| X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/a… | homo-2-mer | 2×UNT; | ||||
| Assess | ||||||
| PPARg bound to partial agonist H3B-487 | homo-2-mer | 2×TJO; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma LBD and the ligand LJ570 [(2S)-3-(biphenyl-4-yl)… | homo-2-mer | 1×AXY; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma with the ligand FS214 | homo-2-mer | 1×RRH; | ||||
| Assess | ||||||
| Crystal Structure of PPARgamma with the ligand JO21 | homo-2-mer | 2×RRG; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma-LBD and the R enantiomer of Mbx-102 (Metaglidase… | homo-2-mer | 1×MGZ; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma-LBD and the S enantiomer of Mbx-102 (Metaglidase… | homo-2-mer | 1×MSZ; | ||||
| Assess | ||||||
| Crystal structure of the complex between PPARgamma LBD and trans-resveratrol | homo-2-mer | 1×STL; | ||||
| Assess | ||||||
| LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | monomer | |||||
| Assess | ||||||
| Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with rosigl… | monomer | 1×BRL; 5×GOL; | ||||
| Assess | ||||||
| X-ray structure of human PPARgamma ligand binding domain-saroglitazar co-crystals obtained by co-cr… | monomer | 1×EWR; | ||||
| Assess | ||||||
| PPAR gamma LBD complexed with the agonist GW1929 | monomer | 1×EDK; 1×FLC; 3×NA; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma (PPARG) in complex with JP85 (compound 1). | monomer | 2×O7O; 5×GOL; | ||||
| Assess | ||||||
| Ligand binding domain of human PPAR gamma in complex with amorfrutin B | monomer | 1×YFB; | ||||
| Assess | ||||||
| Ligand binding domain of human PPAR gamma in complex with amorfrutin 2 | monomer | 1×YFD; | ||||
| Assess | ||||||
| Ligand binding domain of human PPAR gamma in complex with amorfrutin 1 | monomer | 1×YFE; | ||||
| Assess | ||||||
| PPAR gamma mutant complex | monomer | 1×EDK; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 | monomer | 2×WY1; | ||||
| Assess | ||||||
| X-ray crystal structure of human ppar gamma with 2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)be… | monomer | 1×ZAA; | ||||
| Assess | ||||||
| Crystal structure of the human PPARg-LBD/rosiglitazone complex obtained by dry co-crystallization a… | monomer | 1×FMT; 1×BRL; | ||||
| Assess | ||||||
| PPAR gamma LBD bound to Inverse Agonist SR10221 | monomer | 2×A8R; | ||||
| Assess | ||||||
| Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with garcin… | monomer | 2×NQD; 1×CIT; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma (PPARG) in complex with SA112 (compound 2). | monomer | 1×GOL; 1×O86; | ||||
| Assess | ||||||
| LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE | monomer | 1×P1B; 1×PE4; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma (PPARG) in an inactive form | monomer | 3×EDO; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphen… | monomer | 1×ZXG; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin | monomer | 1×XPT; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma in complex with compound TK90 | monomer | 1×TK9; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma in complex with compound FL217 | monomer | 1×5IV; 1×SO4; 6×EDO; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma in complex with compound (R)-16 | monomer | 1×MLQ; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma in complex with compound 16 (MF27) | monomer | 1×MLQ; | ||||
| Assess | ||||||
| Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG) in complex with TETRAC | monomer | 1×T4A; | ||||
| Assess | ||||||
| Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor gamma agonist | monomer | 1×Y1N; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 13-(S)-HODE | monomer | 1×243; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with DHA | monomer | 1×HXA; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA) | monomer | 1×XDI; 1×PGO; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA) | monomer | 1×XDH; 1×PGO; | ||||
| Assess | ||||||
| Crystal structure of PPARgammaLBD complexed with the agonist magnolol | monomer | 2×MLO; | ||||
| Assess | ||||||
| Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist | monomer | 1×EHA; | ||||
| Assess | ||||||
| Human PPAR gamma in complex with nonanoic acids | monomer | 3×KNA; 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Edaglitazone | monomer | 2×8A7; 1×KNA; | ||||
| Assess | ||||||
| Human PPARgamma in complex with MEHP bound to the AF-2 and omega sub-pockets | monomer | 2×QGL; | ||||
| Assess | ||||||
| PPARgamma ligand binding domain in complex with sulindac sulfide | monomer | 2×SFI; | ||||
| Assess | ||||||
| PPAR gamma ligand binding domain in complex with MRL-871 | monomer | 1×4F1; 1×GOL; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 6-oxoOTE | monomer | 1×6OC; | ||||
| Assess | ||||||
| Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid | monomer | 1×ET0; | ||||
| Assess | ||||||
| PPARgamma ligand binding domain in complex with indomethacin | monomer | 2×IMN; | ||||
| Assess | ||||||
| PPARg LBD bound to SR10171 | monomer | 2×EKS; | ||||
| Assess | ||||||
| Crystal structure of PPARg-LBD complexed with three partial agonists, one nTZDpa and two LT175 | monomer | 1×NZA; 2×LRG; | ||||
| Assess | ||||||
| Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone | monomer | 1×BRL; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma in complex with NMP422 | monomer | 1×G3S; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA | monomer | 1×4M5; | ||||
| Assess | ||||||
| PPARg LBD bound to SR11023 | monomer | 1×EKP; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Hydroxy Pioglitazone (M-… | monomer | 1×GFV; 2×KNA; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Darglitazone | monomer | 1×GEV; | ||||
| Assess | ||||||
| Crystal structure of PPARgamma ligand-binding domain in complex with ZINC5672437 | monomer | 1×XZK; 1×KNA; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 4-HDHA | monomer | 1×4HD; | ||||
| Assess | ||||||
| Crystal structure of human PPARgamma ligand binding domain (Protein delipidated by denature and ref… | monomer | |||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Nonanoic acid | monomer | 1×GW9; 1×KNA; | ||||
| Assess | ||||||
| Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid | monomer | 2×KNA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 2… | monomer | 1×AZ2; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid | monomer | 1×66B; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10506 | monomer | 1×GBV; | ||||
| Assess | ||||||
| Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket | monomer | 1×QG6; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with MSDC-0602 | monomer | 1×GH1; 1×KNA; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 | monomer | 1×BXG; 1×KNA; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Ciglitazone | monomer | 1×LO4; | ||||
| Assess | ||||||
| Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma | monomer | 2×AJA; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with TRAP220 Coactivator Pept… | monomer | |||||
| Assess | ||||||
| High Resolution Structure of Peroxisone Proliferation-Activated Receptor gamma and Characterisation… | monomer | |||||
| Assess | ||||||
| PPAR gamma mutant complex | monomer | 1×EDK; 1×IOD; 3×CL; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 9-(S)-HODE | monomer | 2×9HO; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Oleic acid | monomer | 1×OLA; | ||||
| Assess | ||||||
| Crystal structure of human PPARgamma ligand binding domain Y473E mutant | monomer | |||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 4-oxoDHA | monomer | 1×4R8; | ||||
| Assess | ||||||
| PPARgamma antagonist (MMT-160)- PPARgamma LBD complex | monomer | 1×5YW; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Oleic Acid | monomer | 1×OLA; | ||||
| Assess | ||||||
| PPARgamma complex with the betulinic acid | monomer | 1×QZQ; | ||||
| Assess | ||||||
| Crystal structure of human PPARgamma ligand binding domain in complex with GW1929 | monomer | 1×EDK; | ||||
| Assess | ||||||
| The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, a… | monomer | 1×538; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Arachidonic Acid | monomer | 1×ACD; | ||||
| Assess | ||||||
| Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with GW1929 | monomer | 1×EDK; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Arachidonic a… | monomer | 1×GW9; 1×ACD; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Rosiglitazone and Oleic … | monomer | 1×BRL; 1×OLA; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 5-oxo-tricosahexaenoic acid | monomer | 1×5OX; | ||||
| Assess | ||||||
| Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with Darglitazone | monomer | 1×GEV; | ||||
| Assess | ||||||
| Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Mitoglitazone | monomer | 1×LO7; 1×KNA; | ||||
| Assess | ||||||
| hPPARgamma Ligand binding domain in complex with 5-HEPA | monomer | 1×5HE; | ||||
| Assess | ||||||
| X-ray Crystal structure of PPARgamma R288H mutant. | monomer | |||||
| Assess | ||||||
| MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | monomer | 1×DIF; | ||||
| Assess | ||||||
| X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound wit… | monomer | 1×HIG; | ||||
| Assess | ||||||
| Crystal structure of PPAR gamma co-crystallized with nTZDpa | monomer | 1×NZA; | ||||
| Assess | ||||||
4 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3e00.1.B | monomer | 0.73 | 2×ZN; 1×GW9; | 100.00 | ||
| Assess | ||||||
| 4nqa.1.A | monomer | 0.55 | 1×ZN; | 31.08 | ||
| Assess | ||||||
| 3dzy.1.A | monomer | 0.54 | 1×ZN; | 31.48 | ||
| Assess | ||||||
| 5uan.1.A | monomer | 0.54 | 2×ZN; | 31.08 | ||
| Assess | ||||||
5 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 3e00.1.B | monomer | 0.78 | 2×ZN; 1×GW9; | 100.00 | |
| Assess | ||||||
| Isoform 2 | 3dzu.1.A | monomer | 0.57 | 1×ZN; | 31.48 | |
| Assess | ||||||
| Isoform 2 | 4nqa.1.A | monomer | 0.56 | 1×ZN; | 31.08 | |
| Assess | ||||||
| Isoform 2 | 5uan.1.A | monomer | 0.55 | 2×ZN; | 31.08 | |
| Assess | ||||||
| Isoform 3 | 3dzu.1.B | monomer | 0.69 | 2×ZN; | 97.22 | |
| Assess | ||||||